Cas:107201-33-2 benzyl N-methyl-N-(2-oxoethyl)carbamate manufacturer & supplier

We serve Chemical Name:benzyl N-methyl-N-(2-oxoethyl)carbamate CAS:107201-33-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

benzyl N-methyl-N-(2-oxoethyl)carbamate

Chemical Name:benzyl N-methyl-N-(2-oxoethyl)carbamate
CAS.NO:107201-33-2
Synonyms:N-Cbz-Methylaminoacetaldehyde;N-benzyloxycarbonyl-N-methylaminoacetaldehyde
Molecular Formula:C11H13NO3
Molecular Weight:207.22600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:46.61000
Exact Mass:207.09000
LogP:1.45390

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-Cbz-Methylaminoacetaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-benzyloxycarbonyl-N-methylaminoacetaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Cbz-Methylaminoacetaldehyde Use and application,N-benzyloxycarbonyl-N-methylaminoacetaldehyde technical grade,usp/ep/jp grade.


Related News: Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” (2S,3R)-2-amino-3-trimethylsilyloxybutanoic acid manufacturers In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April. (2S)-3-(3,4-dihydroxyphenyl)-2-(methylamino)propanoic acid suppliers Joan Merrill, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, US, said: “Arthritis and rash are the most common and persistent problems in lupus and often have a significant impact on a person’s life. The strength of the data from this analysis is that anifrolumab was found to be consistently effective using three different ways of looking at rash and three different approaches to arthritis. 3-(4-bromophenyl)benzo[d]isothiazol-6-ol vendor & factory.